🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  2. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  3. Radiotherapy plus temozolomide

    The First People's Hospital of Lianyungang

    Glioma (Any Grade) in the Brain

    phase 2 small molecule active

    1 trial

  4. Raltitrexed

    The First People's Hospital of Lianyungang

    Inoperable Esophageal Cancer Stage I-III

    phase 2 small molecule active

    1 trial

  5. Recombinant COVID-19 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  6. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  7. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  8. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Recombinant Interferon Alpha

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Essential Thrombocytopenia

    phase 2 small molecule active

    2 trials

  10. Recombinant human endostatin

    The First People's Hospital of Lianyungang

    Stage III Non-small-Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. Regorafenib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Regorafenib

    phase 2 small molecule active

    1 trial

  12. Remote ischemic preconditioning (RIPC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cerebrovascular Disease

    phase 2 other completed

    1 trial

  13. Repigel

    Hospital Authority, Hong Kong

    Acne

    phase 2 small molecule active

    1 trial

  14. Revlimid 25 mg hard capsules, Isatuximab, Dexamethasone Tablets 2 mg, Revlimid 15 mg hard capsules, Isatuximab, VELCADE 1 mg powder for solution for injection, Revlimid 10 mg hard capsules

    Ningbo Cancer Hospital

    Newly diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  15. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial

  16. Rifaximin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Intestine Bacterial Overgrowth

    phase 2 small molecule active

    1 trial

  17. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  18. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Severe Aplastic Anemia

    phase 2 small molecule active

    1 trial

  19. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Rituximab Paclitaxel Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  22. Romiplostim

    The First People's Hospital of Lianyungang

    MDS (Myelodysplastic Syndrome)

    phase 2 small molecule active

    1 trial

  23. Romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule completed

    1 trial

  24. Romiplostim N01

    Hospital Authority, Hong Kong

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources